Restoration of defective cross-presentation in tumors by gemcitabine

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)


© 2015 Taylor & Francis Group, LLC. Tumor antigen cross-presentation by dendritic cells (DCs) to specific CD8+ T cells is central to antitumor immunity. Although highly efficient in draining lymph nodes, it is defective within the tumor site itself. Importantly, an immunogenic chemotherapy, gemcitabine, reverses this defect, allowing the potential re-stimulation of cytotoxic T lymphocytes within tumor sites.
Original languageEnglish
Pages (from-to)e1005501
Issue number5
Publication statusPublished - 2015


Dive into the research topics of 'Restoration of defective cross-presentation in tumors by gemcitabine'. Together they form a unique fingerprint.

Cite this